|
|
America has long been the world’s premier destination for medical innovation. Our universities make groundbreaking discoveries. Our biotechnology companies turn them into medicines. Our capital markets finance risks few other countries can match. And the U.S. Food and Drug Administration ensures patient safety and efficacy.
This leadership can’t be taken for granted.
Today, a first-in-human clinical trial can take years to initiate in the United States versus just months in China and Australia. When clinical development happens faster overseas, America risks losing investment, intellectual property, scientific talent and, most important, early access to promising new therapies.
That is why the FDA is launching the Expedited Investigational New Drug (IND) Pilot today. This is a key priority of the Trump Administration to retain American leadership in biomedical advancements.
|
|
|
|
